ライフサイエンスコーパス: Flt3 ligand

1 n DC development in vitro in the presence of Flt3 ligand.

2 okine combination of steel factor, IL-7, and Flt3 ligand.

3 rentiation into IPCs/pre-DC2 in culture with FLT3 ligand.

4 -1 myeloid leukemia cells indicates that the FLT3 ligand.

5 a cell lines (n = 5) bound little to no 125I-FLT3 ligand.

6 in cultures of BM precursors stimulated with Flt3 ligand.

7 0 even after the induction of high levels of Flt3 ligand.

8 th sites shared an intrinsic requirement for Flt3 ligand.

9 odies (mAb) capable of preventing binding of FLT3 ligand.

10 nerated from mouse bone marrow cultures with FLT3-ligand.

11 on BM stromal cells supplemented with IL-7 + FLT3-ligand.

12 cells supplemented with interleukin (IL)-7 + FLT3-ligand.

13 or (M-CSFR) and Fms-like thyrosine kinase 3 (Flt3) ligands.

14 is could be accelerated therapeutically with flt3 ligand, a growth factor that stimulates the differe

15 Treatment with Flt3 ligand, a hematopoietic growth factor that dramatic

16 t treatment of advanced cancer patients with Flt3 ligand, a hematopoietic growth factor, expanded DCs

17 Abs against lymphotoxin A, TNF-alpha, and/or flt3 ligand abolished the ability of CS1 on the B cell p

18 iven nasal OVA plus an adenovirus expressing Flt3 ligand (Ad-FL) showed early expansion of CCR5(+)/CC

19 We have recently shown that Flt3 ligand administration dramatically increases dendri

20 ins to the minimization of recombinant human Flt3 ligand aggregation and its potential role for deter

21 l in pDCs generated in vitro by culture with Flt3 ligand and ex vivo in sorted splenic pDCs.

22 number of TIDCs, the therapeutic benefit of Flt3 ligand and GM-CSF treatment is minimal.

23 of the IL-7R, and require costimulation with Flt3 ligand and IL-7 to generate B cells in vitro.

24 sarcomas with the combination of recombinant Flt3 ligand and recombinant granulocyte-macrophage colon

25 t numbers of DCs to peripheral tissues using Flt3 ligand and then delivering a tumor-associated Ag an

26 ) myeloid DCs is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulatin

27 cyte macrophage colony-stimulating factor or FLT3 ligand) and costimulation by agonistic alpha-4-1BB

28 au, amyloid beta peptide 1-42 (Abeta(1-42)), Flt3 ligand, and fractalkine levels in CSF in a large co

29 ted the antitumor effect of PD-1 antibody or Flt3 ligand, and induced the presentation of a TAP-indep

30 rs such as stem cell factor, thrombopoietin, Flt3 ligand, and interleukins have shown promising resul

31 egative murine marrow cells cultured in TPO, Flt3 ligand, and SCF, without affecting the rate of cell

32 The combination of thrombopoietin, Flt3 ligand, and stem cell factor upregulated survivin e

33 colony-stimulating factor, stem cell factor, flt3 ligand, and thrombopoietin, to this SCEPF activity.

34 ukin 3 (IL-3), IL-6, stem cell factor (SCF), Flt3 ligand, and thrombopoietin.

35 ls to the early-acting cytokines kit ligand, flt3 ligand, and thrombopoietin.

36 -stimulating factor, stem cell factor, flk-2/flt3 ligand, and thrombopoietin.

37 response to a cocktail of stem cell factor, flt3 ligand, and thrombopoietin.

38 -M-DC CM was the only one that enhanced SCF, Flt3 ligand, and TPO expansion of myeloid progenitor cel

39 ow arises as to whether these high levels of FLT3 ligand are actually promoting relapse, and, if so,

40 Unexpectedly, a robust Flt3 ligand-associated proliferative recovery response s

41 or megakaryocyte nuclear maturation, nor did FLT3 ligand augment the effects of thrombopoietin on the

42 Scatchard analysis of 125I-FLT3 ligand binding data shows that three myeloid leukem

43 gand production was established; whereas the Flt3 ligand blunted the inhibitory effects of AC220, the

44 responsive to superphysiological amounts of Flt3 ligand but was not dependent on Flt3 for its homeos

45 Flt3 ligand, but not thymic stromal-derived lymhopoietin

46 Human Flt3 ligand can expand dendritic cells (DC) and enhance

47 te-macrophage colony-stimulating factor, and Flt3 ligand, CD45+/lineage-/c-kit+/FcepsilonRI+ cells be

48 Following treatment of mice with Flt3 ligand, coadministration of immunostimulatory DNA a

49 ysozyme(+)) colonies when grown in IL-7- and Flt3 ligand-containing media.

50 on between DCs and cell-free HTLV-1, we used FLT3 ligand-cultured mouse bone marrow-derived DCs (FL-D

51 B cells from Flt3 ligand-deficient mice have impaired IL-4R signaling

52 Absence of Flt3 signaling in Flt3 ligand-deficient mice results in impaired IgG1 CSR

53 Flt3 ligand-dependent generation of CD8alpha(+) cDCs in

54 ir virtual lack of IL-12 production, whereas Flt3 ligand-derived dendritic cells produced IL-12 and a

55 oreover, NOD bone marrow cells cultured with Flt3-ligand developed a heat-stable antigen-positive/Ly6

56 FLT3 ligand did not promote colony forming unit megakary

57 By contrast, in Flt3 ligand-driven DC differentiation, activation of AF-

58 l (E2) has been shown to regulate GM-CSF- or Flt3 ligand-driven dendritic cell (DC) development throu

59 Hence, we characterized the response to FLT3 ligand during cDC1 and cDC2 lineage differentiation

60 (CD135), and stimulation of the receptor via FLT3 ligand either in vivo or in vitro is known to drive

61 was expanded in media containing recombinant flt3 ligand, erythropoietin, and PIXY321, using stromal-

62 e CD4 T cells, trapping the cells in a naive Flt3 ligand-expressing state.

63 highly conserved, 18 aa sequence within the flt3 ligand extracellular domain is required for flt3 re

64 or numerous growth factors (kit ligand [KL], FLT3 ligand, fibroblast growth factor-2 [FGF-2], vascula

65 hen AMD3100 (day 10) was coadministered with Flt3 ligand (FL) (days 1-10) and granulocyte colony-stim

66 increases in donor liver DC as the result of Flt3 ligand (FL) administration and the resulting augmen

67 Systemic Flt3 ligand (FL) administration in mice induced a signif

68 igh cells were maintained in the presence of Flt3 ligand (FL) alone, and increased in response to FL

69 hereby extrinsic microenvironmental proteins FLT3 ligand (FL) and fibroblast growth factor 2 (FGF2) p

70 was recognized that other factors including flt3 ligand (FL) and G-CSF expand various DC subsets in

71 Here we investigated the effect of flt3 ligand (FL) and granulocyte colony-stimulating fact

72 e CD11c(+)B220(+) pDCs can be generated with Flt3 ligand (FL) as the sole exogenous differentiation/g

73 e tyrosine kinase activity in the absence of FLT3 ligand (FL) binding, and when expressed in cytokine

74 istration of a naked cDNA plasmid expressing Flt3 ligand (FL) cDNA (pFL) enhanced CD4(+) Th2-type, cy

75 Treatment of mice with human Flt3 ligand (FL) dramatically increases the number of DC

76 Flt3 ligand (FL) dramatically increases the number of im

77 The cytokine FLT3 ligand (FL) enhances dendritic cell (DC) generation

78 Flt3 ligand (FL) enhances hematopoietic cell proliferati

79 In this study, we assessed a cDNA vector for Flt3 ligand (FL) for its potential to enhance mucosal im

80 We recently showed that the flt3 ligand (FL) has a unique ability to interact with i

81 Flt3 ligand (FL) has been proposed as a possible modulat

82 studies using stroma-free short term assays, Flt3 ligand (FL) has been shown to induce proliferation

83 Mice deficient for Hoxa9, Flt3, or Flt3 ligand (FL) have reduced numbers of lymphoid-primed

84 We have investigated the role of flk2/flt3 ligand (FL) in B cell lymphopoiesis.

85 , we report a synergistic role for IFN-I and Flt3 ligand (FL) in pDC development from common lymphoid

86 To expand on the functional properties of Flt3 ligand (FL) in vivo we treated nonhuman primates wi

87 Daily injection of mice of Flt3 ligand (FL) into mice transiently expands both subs

88 Flt3 ligand (FL) is a hematopoietic growth factor that i

89 Flt3 ligand (FL) is a member of a small family of growth

90 Flt3 ligand (FL) is a potent hemopoietic growth factor t

91 sed patients, we investigated whether plasma FLT3 ligand (FL) levels could influence the efficacy of

92 We hypothesized that the cytokine FLT3 ligand (FL) might be able to replace the maintenanc

93 lation of wild-type (WT) FLT3 by coexpressed FLT3 ligand (FL) occurs in many other cases.

94 ietic stem-progenitor cell mobilizing factor flt3 ligand (FL) on donor leukocyte microchimerism in no

95 The effects of a novel cytokine FLK2/FLT3 ligand (FL) on human fetal bone marrow-derived CD34

96 The effect of chronic expression of flt3 ligand (FL) on in vivo hematopoiesis was studied.

97 igated the effects of in vivo treatment with flt3 ligand (FL) on murine hematopoiesis, including mobi

98 ery followed by intramyocardial injection of FLT3 ligand (FL) or vehicle into the infarct border zone

99 Systemic treatment with Flt3 ligand (FL) results in a marked increase of DCs in

100 Administration of FLT3 ligand (FL) results in a reversible accumulation of

101 burn-injured mice with the DC growth factor FLT3 ligand (FL) significantly increases resistance to b

102 The recently cloned flt3 ligand (FL) stimulates the growth of primitive hema

103 ion of FLT3-transfected cells was delayed by FLT3 ligand (FL) stimulation.

104 ats 1-4, 5b, or 6, was potently activated by Flt3 ligand (FL) stimulation.

105 IMC-EB10 blocks the binding of FLT3 ligand (FL) to soluble FLT3 in ELISA and competes w

106 Notably, Flt3 ligand (FL) treatment of NOD donors expanded FC tot

107 timulation, and both expand and mature after Flt3 ligand (FL) treatment.

108 Here we show that administration of Flt3 ligand (FL), a cytokine capable of inducing large n

109 cible system to conditionally express murine Flt3 ligand (FL), a potent hemopoietic growth factor tha

110 al different growth factors, including human flt3 ligand (FL), alone and in combination with granuloc

111 factors, interleukin-2 (IL-2), IL-12, IL-15, Flt3 ligand (FL), and granulocyte-macrophage colony-stim

112 ulation of survivin by thrombopoietin (Tpo), Flt3 ligand (FL), and stem cell factor (SCF) occurred in

113 pare and contrast the expression patterns of Flt3 ligand (FL), c-Kit ligand (KL), and macrophage colo

114 imiting dilutions with interleukin-7 (IL-7), flt3 ligand (FL), c-kit ligand (KL), IL-3, IL-2, and AFT

115 owth, but synergized with c-kit ligand (KL), flt3 ligand (FL), or IL-3 to potently enhance clonogenic

116 he recently cloned hemopoietic growth factor flt3 ligand (FL), which is highly effective in mobilizin

117 k itself was tyrosine phosphorylated by both FLT3 ligand (FL)-activated FLT3-WT and constitutively ac

118 Flt3 ligand (FL)-derived DC function was tested as a sti

119 se domain (TKD) appear to activate FLT3 in a FLT3 ligand (FL)-independent manner.

120 bopoietin (TPO), c-kit ligand (KL), and flk2/flt3 ligand (FL).

121 he recently cloned hemopoietic growth factor Flt3 ligand (FL; 10 microg/day for 10 days) resulted in

122 Fms-like tyrosine kinase-3 (Flt3) ligand (FL) and Interleukin-7 (IL-7) are cytokines

123 Fms-related tyrosine kinase 3 (Flt3)-ligand (FL) promotes the proliferation, differenti

124 re injected with Fms-like tyrosine kinase 3 (Flt3)-ligand (FL) to expand dendritic cells (DCs) and we

125 Injection of mice with the cytokine Flt3-ligand (FL) dramatically expands mature lymphoid an

126 leukin-3 (IL-3), stem cell factor (SCF), and flt3-ligand (FL) for a 36-hour incubation period during

127 phage colony-stimulating factor (GM-CSF) and flt3-ligand (FL) induce the development of dendritic cel

128 FLT3-ligand (FL) is a recently described cytokine that s

129 inant chimera of the extracellular domain of Flt3-ligand (FL) linked to a model antigen may potential

130 aper we report that administration of either Flt3-ligand (FL) or G-CSF to healthy human volunteers dr

131 Treatment with stem cell factor (SCF), Flt3-ligand (FL), IL-3, and GM-CSF and measurement by mu

132 consisting of either stem cell factor (SCF), Flt3-ligand (FL), interleukin-3 (IL-3), or IL-6 for 7 da

133 In the present study, the flt3-ligand (FL), which, in combination with other cytok

134 Here we describe a flt3-ligand (FL)-dependent BM culture system that genera

135 s in IL-6, IL-7, stem cell factor (SCF), and flt3 ligand (flt3-L) for 5-6 d followed by IL-15 alone f

136 Flt3 ligand (Flt3-L) is a growth factor for dendritic ce

137 Flt3 ligand (Flt3-L) is critical for instructing DC gene

138 intracellular bacteria, we treated mice with Flt3 ligand (Flt3-L) to increase DCs in vivo and challen

139 ned the in vivo effects of recombinant human Flt3 ligand (Flt3-L), a recently cloned potent hemopoiet

140 lished a humanized mouse model incorporating FLT3-ligand (FLT3-L) administration after hematopoietic

141 ed the utility of a novel protocol involving Flt3-ligand (Flt3-L) and granulocyte colony-stimulating

142 Flt3-Ligand (Flt3-L) is a stimulatory cytokine for a var

143 Flt3-ligand (Flt3-L) is an early acting costimulatory cy

144 FLT3-ligand (FLT3-L) represents a key IPC differentiatio

145 We assessed the in vivo efficacy of Flt3-ligand (Flt3-L) treatment in C57BL/6 mice bearing a

146 The cytokine Flt3 ligand (Flt3L) also has been shown to generate BM D

147 CL12 expression after HSPC mobilization with Flt3 ligand (Flt3L) and stem cell factor (SCF).

148 response were enhanced by prior injection of Flt3 ligand (Flt3L) at a dose and schedule that signific

149 The cytokine Flt3 ligand (Flt3L) controls the development of DCs and

150 overexpression of the hematopoietic cytokine Flt3 ligand (Flt3L) expands NKDC in various organs from

151 Here we show that, like GM-CSF, the cytokine Flt3 ligand (Flt3L) expressed in B16 and coupled with CT

152 Flt3 ligand (flt3L) has potent effects on hemopoietic pr

153 the present study, daily injection of human Flt3 ligand (Flt3L) into mice results in a dramatic nume

154 The flt3 ligand (flt3L) is a growth factor for hematopoietic

155 The cytokine Flt3 ligand (Flt3L) is critical for the generation and m

156 Flt3 ligand (Flt3L) is transiently induced in the serum

157 Mobilization of mice with Flt3 ligand (Flt3L) or Flt3L and granulocyte-macrophage

158 onough sarcoma-like tyrosine kinase 3 (FLT3)/FLT3 ligand (FLT3L) pathway is associated with pathogene

159 The Flt3-Flt3 ligand (Flt3L) pathway is critically involved in th

160 Flt3 ligand (Flt3L) potently induced equal expansion of

161 Flt3 ligand (Flt3L) promotes survival of lymphoid progen

162 ll homeostasis and adaptive immunity through Flt3 ligand (Flt3l) release.

163 FLT3 ligand (FLT3L) stimulates primitive hematopoietic c

164 Indeed, flt3 ligand (flt3L) treatment of athymic mice subjected

165 c into immunogenic APC by treating mice with Flt3 ligand (Flt3L), a DC growth factor, and then immuni

166 immunity and tolerance, we treated mice with Flt3 ligand (Flt3L), a growth factor that expands DC in

167 and used as vaccines or generated in vivo by Flt3 ligand (Flt3L), a potent stimulator of DC and natur

168 culture in IL-7, stem cell factor (SCF), and flt3 ligand (flt3L), followed by IL-15 alone.

169 ion (ITD) in FLT3, the receptor for cytokine FLT3 ligand (FLT3L).

170 etreatments with fms-like tyrosine kinase-3 (Flt3) ligand (Flt3L), a dendritic cell growth factor, in

171 We hypothesized that Flt3-ligand (Flt3L) therapy, which expands DCs in vivo,

172 model, we developed protocols for measuring Flt3 ligand (Flt3lg) and serum amyloid A1 (Saa1) in smal

173 ere cultured with IL-7, stem cell factor and flt3 ligand, followed by IL-15, they were able to differ

174 of macrophage colony-stimulating factor and flt3 Ligand for 6 days to generate monocytic cells at al

175 ocompatibility complex class II, and require FLT3 ligand for development (T(DC)).

176 rom myeloid progenitors and are dependent on Flt3-ligand for their development.

177 oma cells expressing either GM-CSF (Gvax) or Flt3-ligand (Fvax) combined with antibody blockade of th

178 These data suggest that Flt3 ligand + GM-CSF therapy of murine tumors fails at a

179 filtration of tumors by CD4(+)CD25(+) TIL in Flt3 ligand + GM-CSF-treated mice, this could reflect th

180 ed medium supplemented with kit ligand, flk2/flt3 ligand, GM-CSF, c-mpl ligand, erythropoietin, and I

181 ily treatment of mice with recombinant human Flt3 ligand (huFlt3L) results in a dramatic numerical in

182 onocytes and DC by conditional expression of Flt3 ligand in animals expressing CCL2 in the CNS promot

183 BM stromal cells are comparable with IL-7 + FLT3-ligand in supporting proliferation of BLIN-4L cells

184 spension culture without FL We conclude that FLT3 ligand, in conjunction with IL-3, IL-6, and SCF, pr

185 In contrast, administration of Flt3 ligand increases the CD11c(hi) DC population, which

186 LIN-4L expansion on BM stromal cells is IL-7/FLT3-ligand independent.

187 IL-6, stem cell factor, thrombopoietin, and Flt3 ligand induced Ccn3/Nov mRNA over 100-fold in WT (c

188 orted exponential growth of L. monocytogenes Flt3 ligand-induced cultures yielded CD103(+)CD11c(+) ce

189 hat TGF-beta2 at low concentrations enhances flt3 ligand-induced growth of HSPCs, while it is potentl

190 inhibition of IFN-alphabeta was observed in FLT3 ligand-induced murine DCs, purified murine myeloid

191 cellularity and also is required to mediate Flt3 ligand-induced NK cell expansion in vivo.

192 and defective in Fms-like tyrosine kinase-3(Flt3) ligand-induced, but not in granulocyte macrophage-

193 ralysis in 100% of the mice within 9 days of Flt3 ligand induction.

194 r the control of fms-like tyrosine kinase 3 (Flt3) ligand, inhibitor of DNA protein 2 (Id2), and IFN

195 spension in the presence of KIT ligand, FLK2/FLT3 ligand, interleukin-6 (IL-6), and erythropoietin wi

196 The rates of FLT3 ligand internalization and degradation were determi

197 FLT3 ligand is a hematopoietic growth factor that plays

198 neage differentiation and find that although FLT3 ligand is required throughout cDC2 differentiation,

199 strated by its failure to inhibit the bovine flt3 ligand isoform 1 binding to the human flt3 receptor

200 ng structure was confirmed by testing bovine flt3 ligand isoform 1 constructs truncated at specific r

201 evel, the extracellular domain of the bovine flt3 ligand isoform 1 is 81 and 72% identical with the e

202 Bovine flt3 ligand isoform 1, but not 2, bound the human flt3 r

203 Two conserved bovine flt3 ligand isoforms, which differ in a defined region w

204 FLT3 ligand levels did not rise to levels seen in prior

205 Overall, we find that tight regulation of FLT3 ligand levels throughout cDC differentiation dictat

206 CS1 activation enhanced mRNA transcripts of flt3 ligand, lymphotoxin A, TNF, and IL-14.

207 landin E(2) (PGE(2)) is required for optimal Flt3 ligand-mediated DC development and regulates expres

208 Because the Flt3 ligand-mediated differentiation pathway is importan

209 little is known about the effects of murine Flt3 ligand (mFlt3L) on mouse DC development and functio

210 -15(-/-) as well as IL-15Ralpha(-/-) but not flt3 ligand(-/-) mice expressed much lower levels of Ly-

211 olonies in the presence of interleukin 7 and flt3 ligand migrate to thymus-expressed chemokine (TECK)

212 In addition, we evaluated the effect of FLT3 ligand on megakaryocytic colony growth and nuclear

213 tiated from the BM of UV-chimeric mice using FLT3 ligand or GM-CSF + IL-4, the cells maintained a red

214 on by granulocyte-colony stimulating factor, flt3 ligand, or both.

215 Particularly, with CSF Flt3 ligand, PD could be clearly differentiated from mul

216 d that a combination of a plasmid-expressing Flt3 ligand (pFL) and CpG oligodeoxynucleotides (CpG ODN

217 mmunized with PspA plus a plasmid expressing Flt3 ligand (pFL) cDNA as a mucosal adjuvant showed sign

218 nce between the opposing forces of AC220 and Flt3 ligand production was established; whereas the Flt3

219 Notably, administration of flt3 ligand rapidly reverses immunoparalysis in vivo, ac

220 FLT3/ITD by lestaurtinib caused by exogenous FLT3 ligand, resistance to sorafenib caused by the D835Y

221 xtracellular domains of the human and murine flt3 ligands, respectively, whereas isoform-2 has a dele

222 t, combination therapy with CD40 agonist and Flt3 ligand restores cDC1 abundance to normal levels, de

223 Stimulation of patient samples with FLT3 ligand resulted in autophosphorylation of the FLT3

224 concentrations of thrombopoietin/Kit-ligand/Flt3-ligand resulted in a 400-fold expansion of total he

225 Strikingly, treatment of NOD mice with Flt3-ligand significantly decreased insulitis and progre

226 ne AFT024 fetal liver stromal cells and with Flt3-Ligand, stem cell factor, and interleukin-7.

227 Overall, the flt3 ligand structure required for function is markedly

228 This definition of the required flt3 ligand structure will facilitate development of ago

229 identify the fetal liver tyrosine kinase 3 (flt3) ligand structure required for binding and function

230 Conversely, in Flt3 ligand-supplemented cultures initiated from the sam

231 t of this, CD1d was required for the SCF and Flt3 ligand synergistic enhancement of CSF induction of

232 They remain highly responsive to FLT3 ligand, the levels of which rise several-fold durin

233 ts on differentiation mediated by GM-CSF and Flt3 ligand, the two cytokines that regulate DC differen

234 38(-) cells derived from FLV were exposed to flt3-ligand, thrombopoietin, stem cell factor (SCF), or

235 nation of Abs against GM-CSF, IL-3, and anti-Flt3 ligand to achieve maximum neutralization.

236 k thermal reversibility to the propensity of Flt3 ligand to aggregate once unfolded in the Tm plateau

237 use bone marrow cells can be used along with Flt3 ligand to conditionally immortalize early hematopoi

238 Crosslinking of 125I-FLT3 ligand to FLT3 receptors on the surface of ML-1 mye

239 New efforts focus on blocking the binding of FLT3 ligand to its receptor as a means of inhibiting aut

240 degradation were determined by binding 125I-FLT3 ligand to ML-1 cells and acid stripping to distingu

241 the FLT3 receptor may target the effects of FLT3 ligand to primitive hematopoietic cells and to myel

242 he regulatory proteins VEGF, HGF, FGF-2, KL, FLT3 ligand, TPO, IL-16, IGF-1, transforming growth fact

243 C3H (H2(k)) recipients of liver grafts from Flt3 ligand-treated B10 donors were given neutralizing a

244 hat the mature DC subsets (C, D, and E) from Flt3 ligand-treated mice differ with respect to phenotyp

245 antially from subsets recruited in normal or Flt3 ligand-treated mice or using GM-CSF protein injecti

246 ed with minimal amounts in DC from normal or Flt3 ligand-treated mice.

247 Finally, postsepsis Flt3 ligand treatment increased the number of DCs and im

248 Therefore, Flt3-ligand treatment and/or the establishment of mixed

249 Internalized 125I-FLT3 ligand was detected within 5 minutes after binding

250 led to protect against tumors in which human Flt3 ligand was protective, but depletion of CD4(+) T ce

251 Flt3 ligand was required during the 7-day ex vivo cultur

252 Using human 125I-FLT3 ligand, we have identified and characterized surfac

253 The levels of blood Flt3 ligand were also measured to evaluate the radioimmu

254 um levels of the hematopoietic growth factor Flt3 ligand were dramatically elevated.

255 nes, ie, G-CSF plus kit ligand or G-CSF plus Flt3-ligand were used with anti-VLA4 in primates and mic

256 s systemic delivery of the DC growth factor, Flt3 ligand, which dramatically increased the number of

257 By contrast, livers from donors treated with Flt3 ligand, which dramatically increases hepatic inters

258 Candidate cytokines included IFN-gamma and Flt3 ligand, which were also produced in response to IL-

259 we combined a dendritic cell growth factor, Flt3 ligand, with a dendritic cell activator, immunostim